In a recently published pilot trial, 44 severe stroke patients (NIHSS>8) were randomized to receive Cerebrolysin (30 ml/day, for 14–21 days, n = 23) or standard therapy (n = 21) following futile reperfusion therapy (r-tPA and/or MT). This evidence concerns the gene PLAT and Stroke.